Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients

European Journal of Cancer

Volumn 42, Issue 5, 2006, Pages 608-616

  Garufi, Carlo ^a   Vanni, Barbara ^a   Aschelter, Anna Maria ^a   Zappalà, Albina Rita ^a   Bria, Emilio ^a   Nisticò, Cecila ^a   Sperduti, Isabella ^a   Cognetti, Francesco ^a   Terzoli, Edmondo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

5 Fluorouracil; Chronomodulation; Colorectal cancer; Irinotecan

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ABDOMINAL CANCER; ABDOMINAL WALL; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE FREE INTERVAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONOTHERAPY; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33644747251     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.03.012     Document Type: Article

References (34)

1. E. Van Cutsem, D. Cunningham, and W.W. Ten Bokkel Huinink Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil Eur J Cancer 35 1999 54 59
2. R.H. Mathijssen, R.J. van Alphen, and J. Verweij Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 7 2001 2182 2194
3. J.Y. Douillard, D. Cunningham, and A. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. A multicentre randomised trial Lancet 355 2000 1041 1057
4. C.H. Kohne, E. Van Cutsem, and J.A. Wils Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986 Proc Am Soc Clin Onocol 22 2003 1018a
5. F. Lévi Circadian chronotherapy for human cancer Lancet Oncol 2 2001 307 315
6. M.C. Mormont, and F. Lévi Cancer chronotherapy: principles, applications and perspectives Cancer 97 2003 155 169
7. G.A. Bjarnason, R.C. Jordan, and P.A. Wood Circadian expression of clock genes in human oral mucosa and skin Am J Pathol 15 2001 1793 1801
8. C. Badiu Genetic clock of biologic rhythms J Cell Mol Med 7 2003 408 416
9. T. Matsuo, S. Yamaguchi, and S. Mitsui Control mechanism of the circadian clock for timing of cell division in vivo Science 10 2003 255 259
10. C. Saccone, C. Maggese, and A.M. D'Erchia Molecular clock and gene function J Mol Evol 57 Suppl. 1 2003 S277 S285
11. C. Garufi, F. Lévi, and A.M. Aschelter A phase I trial of 5-day chronomodulated infusion of fluorouracil and l-folinic acid in patients with metastatic colorectal cancer Eur J Cancer 33 1997 1566 1571
12. H. Cure, V. Chevalier, and A. Adenis Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer J Clin Oncol 20 2002 1175 1181
13. F. Lévi, B. Perpoint, and C. Garufi Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous infusion at circadian rhythm modulated rate Eur J Cancer 29A 1993 1280 1284
14. F. Lévi, J.L. Misset, and S. Brienza A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiviness against metastatic colorectal cancer Cancer 69 1992
15. F. Bertheault-Cvitkovic, A. Jami, and M. Ithzaki Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer J Clin Oncol 14 1996 2950 2958
16. E. Filipski, F. Lévi, and N. Vadrot Circadian changes in irinotecan toxicity in mice Proc AACR 38 1997 2048
17. S. Ohdo, T. Makinosumi, and T. Ishizaki Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice J Pharmacol Exp Ther 283 1997 1383 1388
18. Giacchetti S., et al. In: Proc ECCO 2001, Lisbona.
19. C. Garufi, L. Dogliotti, and R.M. D'Attino Irinotecan and chronomodulated infusionof 5-fluorouracil and folinic acid in the tratment of patients with advanced colorectal carcinoma. A phase I study Cancer 91 2001 712 720
20. C. Garufi, A.R. Zappalà, and A.M. Aschelter Comparison between bolus and chronomodulated CPT11 to chrono 5FU and folinic acid in advanced colorectal cancer patients Proc Am Soc Clin Oncol 21 2002 [abs. 692]
21. A.B. Miller, B. Hoogstraten, and M. Staquet Reporting results of cancer treatment Cancer 47 1981 207 215
22. J. MacDonald, D. Haller, and R. Mayer Grading of toxicity J. MacDonald D. Haller R. Mayer Manual of oncologic therapeutics 1995 Lippincott Philadelphia, PA 519 523
23. R.P. Hern Sample size tables for exact single-stage phase II designs Stat Med 20 2001 859 866
24. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observation J Am Stat Assoc 53 1958 475 481
25. Y. Ohe, Y. Sasaki, and T. Shinkai Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion J Natl Cancer Inst 84 1992 972 974
26. C.H. Takimoto, G. Morrison, and N. Harold Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients J Clin Oncol 18 2000 659 667
27. G. Masi, A. Falcone, and A. Di Paolo A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed Clin Cancer Res 10 2004 1657 1663
28. Giacchetti S, Bjarnason GA, Garufi C, et al. Firstnline infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer: 4-day chronomodulated (FFL4-10) versus 2-day FOLFOX2. A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer (EORTC 05963). Proc ASCO 2004, abs 3526.
29. W. Scheitauer, G.B. Kornek, and M. Raderer Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 21 2003 1307 1312
30. M. Buyse, P. Thiron, and R.W. Carlson Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer Lancet 356 2000 373 378
31. S.E. Sephton, R.M. Sapolsky, and H.C. Kramer Diurnal cortisol rhythm as a predictor of breast cancer survival J Natl Cancer Inst 92 2000 994 1000
32. M.C. Mormont, J. Waterhouse, and P. Bleuzen Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status Clin Cancer Res 6 2000 3038 3045
33. S. Ohdo, S. Koyanagi, and H. Suyama Changing the dosing schedule minimizes the disruptive effects of interferon on clock function Nat Med 7 2001 356 360
34. S. Koyanagi, and S. Ohdo Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism Mol Pharmacol 62 2002 1393 1399